This ICR collects information from dietary supplement and non-prescription drug manufacturers and distributers seeking to introduce these products into interstate commerce under the FFDCA. Respondents provide the agency with proposed labeling for their products as required under the applicable statutes and FDA clears the labeling to ensure compliance so the products can be marketed. Products that do not comply with the applicable labeling regulations may be misbranded and subject to enforcement action.
FDA is requesting to extend approval of the ICR, for which there is a decrease in burden. The burden change is due to an adjustment based on the agency's determination that the number of disclosures per respondent, the total annual number of disclosures, the average burden per disclosure, and the total annual hour burden have decreased.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.